Key takeaways
- A new JAMA Pediatrics study highlights a major surge in teen GLP-1 prescriptions between 2017 and 2025.
What happened
Teenage prescriptions for GLP-1 medications experienced a dramatic surge from 2017 to 2025, according to a newly published study in JAMA Pediatrics. Despite this rapid rise in clinical utilization, researchers found that 90% of adolescents who met the criteria for bariatric surgery still did not receive either medication or surgical intervention.
Why it matters
For parents navigating the complex landscape of childhood obesity, this data highlights a massive care gap in the United States. While clinical guidelines increasingly support early intervention for severe adolescent obesity, traditional insurance hurdles and a shortage of pediatric specialists leave nine out of ten eligible teens without access to approved therapies.
This dramatic mismatch between medical need and clinical access is driving a growing number of families to look beyond traditional pediatric offices. To bridge the gap, parents are turning to online healthcare. Cash-pay telehealth platforms are expanding their services to meet this demand, offering virtual consultations and structured weight-management programs designed to help families secure these highly effective medications when local options fall short.
What the data says
The study, highlighted by MedPage Today, tracked GLP-1 prescribing patterns among teenagers who met the medical criteria for bariatric surgery between 2017 and 2025. The data revealed two contrasting trends:
- A massive prescribing surge: The rate of teens receiving GLP-1 prescriptions increased dramatically over the study's eight-year window.
- Persistent undertreatment: Despite the surge, 90% of eligible adolescents went without any formal medical or surgical intervention for their obesity.
This persistent undertreatment remains a major concern because severe adolescent obesity is closely linked to long-term health complications. Additionally, the World Health Organization (WHO) is launching two new clinical guidelines focused on the integrated management of obesity in children and adolescents, further underscoring the global medical consensus that early intervention is necessary.
How it compares
For families considering weight-loss therapies, understanding the drug options and associated costs is critical. Currently, Wegovy (semaglutide) is FDA-approved for chronic weight management in pediatric patients aged 12 and older. Zepbound (tirzepatide) is widely used off-label or under specific clinical guidance for older teens, though its formal pediatric indications are still evolving.
When comparing these options, families face a stark divide between brand-name medications and telehealth alternatives:
- Brand-Name Costs: Out-of-pocket costs for brand-name Wegovy or Zepbound frequently exceed $1,000 per month if commercial insurance denies coverage.
- The Compounded Alternative: Many families utilize compounded vs. brand-name semaglutide to bypass high retail prices. Compounded options, typically sourced by online clinics, generally cost between $200 and $400 per month, including the virtual medical consultation.
- The Telehealth Landscape: Parents looking to compare costs can use resources like the guide to the cheapest telehealth GLP-1 providers to find clinical programs that offer transparent monthly subscription models rather than high upfront specialist fees.
How this fits the bigger picture
The massive rise in adolescent GLP-1 usage mirrors broader pediatric trends we have previously analyzed. In our coverage of how Wegovy reverses pediatric obesity, clinical trial data demonstrated that semaglutide could reverse obesity in up to 40% of pediatric patients, explaining why demand among parents has skyrocketed. Furthermore, as discussed in our article on pediatric obesity and kidney disease, early intervention is vital because severe childhood obesity is linked to a ninefold increase in lifetime kidney disease risk and a 40fold risk of liver-related mortality.
However, treating teenagers with these powerful metabolic therapies requires strict clinical oversight. In our analysis of how teens on GLP-1s face nutritional deficiencies, we highlighted that nearly 17% of adolescents using these medications develop key nutritional deficits due to rapid appetite suppression. This risk emphasizes why families should avoid low-cost "prescription-only" mills and instead seek out comprehensive telehealth programs found on our providers list, which integrate pediatric-appropriate medical supervision, dietary counseling, and routine monitoring.
What happens next
As pediatric guidelines from organizations like the WHO continue to evolve, the medical community is expected to push for broader insurance coverage of adolescent weight-loss treatments. Additionally, researchers are increasingly focusing on what happens when patients stop these therapies.
For example, researchers at UTHealth Houston recently secured a $4 million grant from the National Institutes of Health (NIH) specifically to identify genetic markers that contribute to weight regain after a patient discontinues GLP-1 medications. The findings from this and other upcoming studies will help providers design safer, more sustainable, long-term weight-maintenance plans for young patients.
Disclaimer: CompareRx does not provide medical advice. Weight-management medications for teenagers require careful evaluation and ongoing supervision by a qualified pediatric healthcare provider.